Enliven Therapeutics
ELVN
93 hedge funds and large institutions have $1.13B invested in Enliven Therapeutics in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 12 closing their positions.
1,950% more call options, than puts
Call options by funds: $287K | Put options by funds: $14K
167% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 12
164% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 14
45% more capital invested
Capital invested by funds: $781M → $1.13B (+$348M)
26% more funds holding
Funds holding: 74 → 93 (+19)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
4.79% less ownership
Funds ownership: 107.51% → 102.72% (-4.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$19.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$17.7M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$16.4M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$16.2M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
5VM
5AM Venture Management
San Francisco,
California
|
-$25.8M |
| 2 |
O
OrbiMed
New York
|
-$21.9M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$20.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.6M |
| 5 |
EAM
Exome Asset Management
New York
|
-$1.01M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MLICM
101
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$22.5K | -1,279 | Closed |
|
102
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$141 | -8 | Closed |
|
|
AWM
103
Avior Wealth Management
Omaha,
Nebraska
| – | -$87 | -5 | Closed |
|
104
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$63 | +3 | +75% |
|
|
C
105
Covestor
London,
United Kingdom
| – | +$105 | +5 | +500% |
|
ELVN Hedge Fund Activity: Q2 2024 in Review
93 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Enliven Therapeutics (ELVN) for Q2 2024, worth a combined $1.13B — up 45% from $781M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ELVN positions and 12 closed out — a net gain of 20 holders — while 37 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $19.3M. The largest seller was 5AM Venture Management, cutting an estimated $25.8M.
- 93 institutional investors held Enliven Therapeutics (ELVN) as of Q2 2024, up from 74 in Q1 2024.
- Funds reported $1.13B of Enliven Therapeutics stock for Q2 2024, up 45% quarter-over-quarter.
- 32 funds opened new Enliven Therapeutics positions in Q2 2024 and 12 closed out, a net change of +20 holders.
- The largest Enliven Therapeutics buyer in Q2 2024 was BlackRock, an estimated $19.3M added.
- The largest Enliven Therapeutics seller in Q2 2024 was 5AM Venture Management, an estimated $25.8M sold.
Based on aggregated 13F filings for Q2 2024.